Non-surgical treatments should not be used if the diagnosis of BCC is unclear
Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Can I request the Certificate of Analysis (COA) for my batch
Connect with us today to discover your ideal treatment path
Seek immediate emergency care (call 911 or go to the emergency department) for: Sudden severe chest pain or pressure Difficulty breathing or shortness of breath at rest Coughing up blood Sudden weakness, numbness, difficulty speaking, vision changes, or severe headache (stroke symptoms) Severe leg pain with swelling and skin color changes Fainting or loss of consciousness Sudden severe abdominal pain (which could indicate pancreatitis, a known rare semaglutide risk) Signs of severe allergic reaction (rash, itching, swelling of face/throat, difficulty breathing) Contact your healthcare provider within 24 hours for: New or worsening leg swelling, especially if unilateral Persistent calf pain or tenderness Unexplained shortness of breath with exertion New onset of rapid heart rate Persistent severe nausea or vomiting preventing adequate hydration Sudden vision changes (potential retinopathy complication) Right upper quadrant pain, fever, or yellowing of skin/eyes (potential gallbladder disease) Markedly decreased urination (potential kidney issue) Positive pregnancy test (semaglutide should be discontinued) Schedule a routine appointment to discuss: Planned surgeries or procedures New medications or supplements Significant changes in activity level or mobility Pregnancy planning (semaglutide should be discontinued at least 2 months before planned conception) Concerns about medication side effects Difficulty with injection technique or medication adherence Patients should generally not discontinue semaglutide abruptly without medical guidance, as this may affect glycemic control in those with diabetes
Tirzepatide is a dual GIP/GLP-1 receptor agonist licensed in the UK for type 2 diabetes, given as a once-weekly subcutaneous injection
